Naples, Florida—March 3, 2020 – Native Cardio announced today that it has been nominated for the prestigious CiteLine award in the category “Most Innovative Start-up Company.” The CiteLine awards, formerly known as the CARE awards, were created to recognize excellence in the many aspects of the biopharmaceutical industry. The awards are open to early- and late-stage research organizations from around the world. The award is sponsored by Medidata, a leading platform for the life sciences.
“The award for most innovative start-up is new this year,” said Dr. Joseph V. Pergolizzi, Jr., the founder of Native Cardio, Inc. “And we are very pleased to have been nominated in this very first year for this prestigious award. It is very gratifying to see that our technology has found resonance in the biotechnical community.”
The CiteLine awards will be given on April 30, 2020 at the Hyatt Regency Hotel in Boston, Massachusetts. There are several categories of awards. This is the first time that Native Cardio, Inc., entered the competition. Dr. Randall Wolf, an arrhythmia specialist at the DeBakey Heart and Vascular Center in Houston Methodist Hospital commented, “Kudos to Native Cardio for this groundbreaking new device. Native Cardio is developing possibly the best new idea for treating postoperative atrial fibrillation to come along in the last 50 years!”
Native Cardio, Inc. is working on a novel medical device designed to treat postoperative atrial fibrillation (AF) using both low-energy cardioversion combined with targeted tissue delivery of drug therapy. “Since we were founded, we have conducted a sort of unique focus group. We’ve asked every key opinion leader we’ve met to give us a reason why Native Cardio should NOT develop this technology,” stated Gary Dixon, Executive Vice President. “And we never heard one yet. The consensus is that Native is in a unique position to address postoperative atrial fibrillation, which is an urgent and largely unmet medical need.”
“Our device could be game-changer,” stated Dr. Pergolizzi, “because there are right now very few effective ways to treat postoperative AF which occurs in about 20% to 40% of all people who undergo heart surgery and 10% to 20% of people who have other types of surgeries. Results from our recent pilot studies have been very promising.”
Native Cardio, Inc. is very pleased to be recognized and will be attending the event in April. For more information about Native Cardio, please visit: native-cardio.com.
About Native Cardio
Native Cardio is a medical device/pharmaceutical development company dedicated to restoring quality of life to patients. Native Cardio is focused on using the latest technologies to develop minimally invasive medical pathways to treat patients safely and effectively. Native Cardio is committed to identifying and addressing current and future unmet medical needs in ways that are cost efficient to the healthcare system.